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Summary
 
Recent studies have identified several coreceptors that are required for fusion and entry of Hu-
man Immunodeficiency Virus type 1 (HIV-1) into CD4
 
1
 
 cells. One of these receptors, CCR5,
serves as a coreceptor for nonsyncytium inducing (NSI), macrophage-tropic strains of HIV-1,
while another, fusin or CXCR-4, functions as a coreceptor for T cell line–adapted, syncytium-
inducing (SI) strains. Using sequential primary isolates of HIV-1, we examined whether viruses
using these coreceptors emerge in vivo and whether changes in coreceptor use are associated
with disease progression. We found that isolates of HIV-1 from early in the course of infection
predominantly used CCR5 for infection. However, in patients with disease progression, the
virus expanded its coreceptor use to include CCR5, CCR3, CCR2b, and CXCR-4. Use of
CXCR-4 as a coreceptor was only seen with primary viruses having an SI phenotype and was
restricted by the 
 
env
 
 gene of the virus. The emergence of variants using this coreceptor was as-
sociated with a switch from NSI to SI phenotype, loss of sensitivity to chemokines, and de-
creasing CD4
 
1
 
 T cell counts. These results suggest that HIV-1 evolves during the course of in-
fection to use an expanded range of coreceptors for infection, and that this adaptation is
associated with progression to AIDS.
 
P
 
rimary isolates of HIV type 1 (HIV-1) show distinct
differences in their biological properties in vitro, in-
cluding differences in replication kinetics, tropism, and syn-
cytium-inducing capacity (1–4). Macrophage-tropic, non-
syncytium-inducing (NSI)
 
1
 
 viruses are most commonly
transmitted and predominate in the early stages of infection
(4–7). Syncytium-inducing (SI) isolates generally appear
later in infection (8, 9) and may acquire an expanded tro-
pism in vitro, including the ability to replicate in CD4
 
1
 
 T
cell lines.
HIV-1 tropism is largely controlled by the 
 
env
 
 gene of
the virus (10–14) which encodes the surface (gp120) and
transmembrane (gp41) envelope glycoproteins. Although
not clearly defined, binding of gp120 to CD4 is believed to
trigger a series of conformational changes, leading to expo-
sure of the NH
 
2
 
-terminal domain of gp41 and subsequent
fusion of the virus and host cell membranes (for review see
reference 15). Despite high affinity binding to gp120, ex-
pression of human CD4 on the surface of nonpermissive
cells is not sufficient to confer susceptibility to HIV-1 in-
fection (16–18), indicating that additional factors are re-
quired for viral fusion and entry to take place.
Recent studies have identified several proteins that serve
as cofactors for HIV-1 fusion with CD4
 
1
 
 T cells (19–24).
These proteins are structurally related, G protein–coupled
receptors characterized by seven transmembrane-spanning
regions (25). One receptor, termed fusin (23) or CXCR-4
(26, 27), has been shown to mediate entry of T cell line–
adapted (TCLA), SI strains of HIV-1 into CD4
 
1
 
 T cells,
but does not permit entry of NSI isolates. A second mole-
cule, CCR5, has recently been identified as a coreceptor for
macrophage-tropic, NSI strains of HIV-1 (20, 21, 24). CCR5
is a member of a family of receptors that bind 
 
b
 
-chemo-
kines, including RANTES, MIP-1
 
a
 
, and -1
 
b
 
 (28). Two
additional 
 
b
 
-chemokine receptors, CCR3 and CCR2b,
have also been shown to function as coreceptors for some,
but not all, primary strains of HIV-1 (19, 22). Taken to-
gether, these findings suggest that HIV-1 may use a broad
range of coreceptors for infection of CD4
 
1
 
 cells.
While disease progression in many HIV-1–infected indi-
viduals is associated with a switch in viral phenotype from
NSI to SI, the ability of HIV-1 isolates to induce syncy-
tium formation is defined largely on the basis of in vitro as-
says (29) with no clear in vivo correlate. We hypothesize
here that the molecular basis of the NSI to SI switch lies in
a change in coreceptor usage from CCR5 to CXCR-4.
Thus far, CXCR-4 has been shown to mediate entry of
 
1
 
Abbreviations used in this paper:
 
 HOS.CD4, human osteosarcoma cells ex-
pressing human CD4; NSI, nonsyncytium-inducing; SI, syncytium-induc-
ing; TCID
 
50
 
, 50% tissue culture infectious dose; TCLA, T cell line–adapted.
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predominantly TCLA strains of HIV-1 (23). However, it is
not yet clear whether primary strains of HIV-1 that use
CXCR-4 emerge during the course of infection, and
whether use of this coreceptor relates to the switch from
NSI to SI phenotype.
Previously, we characterized in detail a series of sequen-
tial primary isolates of HIV-1 from three infected patients
(5). Two of these patients experienced a switch in viral
phenotype from NSI to SI followed by a marked drop in
CD4
 
1
 
 T cell counts and the onset of AIDS. The third pa-
tient remained clinically stable with only NSI isolates for
more than 10 yr after HIV-1 infection. Using sequential
isolates from all three patients, we examined the coreceptor
use and determined whether disease progression, marked
by a switch from NSI to SI phenotype, was associated with
the emergence of variants able to use CXCR-4 as a core-
ceptor, and whether this adaptation was associated with
CD4
 
1
 
 T cell decline in vivo. We show here that HIV-1
uses primarily a single receptor, CCR5, in the early stages
of infection. However, the virus expands its coreceptor use
to include CCR5, CCR2b, CCR3, and CXCR-4 in pa-
tients with disease progression. The ability to use CXCR-4
as a coreceptor was only seen with viruses having an SI
phenotype and was restricted by the 
 
env
 
 gene of the virus.
The emergence of these viruses was associated with a drop
in CD4
 
1
 
 T cell counts and clinical progression in the pa-
tients we studied.
 
Materials and Methods
 
Study Subjects.
 
Sequential isolates of HIV-1 were obtained
from two individuals, B and C, both of whom progressed rapidly
to AIDS after seroconversion. Each patient experienced a precip-
itous drop in CD4
 
1
 
 T cell counts that was preceded by an in-
crease in viral load and a switch in viral phenotype from NSI to
SI (5). Sequential isolates were also evaluated from patient D, who
remained asymptomatic for more than a decade after HIV-1 in-
fection (5). Isolates from this patient spanned a 5-yr period during
which time he was clinically stable with a low viral load and nor-
mal CD4
 
1
 
 T cell counts. All of the isolates from patient D had an
NSI phenotype (5).
 
Generation of Primary Isolates and Biological Clones.
 
Primary iso-
lates of HIV-1 were obtained by a quantitative co-culture
method as previously described (5, 30). In brief, cryopreserved
patient PBMCs were thawed and the cells serially diluted fourfold
in replicates of 4–10 (from 1 
 
3
 
 10
 
6
 
 down to 
 
z
 
10
 
3
 
). The cells
were added to wells containing 2 
 
3
 
 10
 
6
 
 PHA-stimulated normal
donor PBMCs and cultured in a final volume of 1.5 ml of RPMI
medium supplemented with 10% FCS, penicillin (100 U/ml),
streptomycin (100 
 
m
 
g/ml), and interleukin-2 (10 U/ml). The
culture supernatants were tested on days 7, 14, and 21 for the
presence of HIV-1 p24 antigen by a commercially available ELISA
assay (Abbott Labs., North Chicago, IL). A culture was consid-
ered positive if the p24 antigen level was 
 
.
 
30 pg/ml. Virus
present in the first well of each dilution series was pooled from
the replicates and propagated by a single short-term (7–14 d) pas-
sage in PHA-activated normal donor PBMCs, while the biologi-
cal clones from patient B were generated by similar propagation
of virus present in the last positive well of each series. The result-
ing stocks were titered on normal donor PBMCs and the 50% tis-
sue culture infectious dose (TCID
 
50
 
) was determined by the
method of Reed and Muench (31). The syncytium-inducing
properties of each isolate were assessed as previously described (5,
30) using the MT-2 cell assay of Koot et al. (29).
 
Cell Lines.
 
Cells lines stably expressing CCR1, CCR2b,
CCR3, CCR4, CCR5, or CXCR-4 were generated as previ-
ously described (32). In brief, retroviral stocks were prepared using
the expression vector pBABE-puro and the appropriate corecep-
tor. Human osteosarcoma cells expressing human CD4 (HOS.CD4)
were infected with the pBABE-puro viruses, and 2 d later the
cells were selected in 1.0 
 
m
 
g/ml puromycin. When the cells be-
came confluent (after 5–7 days), they were maintained in DMEM
containing puromycin, 10% FCS, penicillin (100 U/ml) and
streptomycin (100 
 
m
 
g/ml).
 
Replication of Sequential HIV-1 Isolates.
 
To assess the corecep-
tor requirements of primary HIV-1 isolates and biologically
cloned isolates, HOS.CD4 (10
 
4
 
/well) expressing either CCR1,
CCR2b, CCR3, CCR4, CCR5, or CXCR-4 were inoculated
with 10
 
3
 
 TCID
 
50
 
 of each isolate in a final volume of 1.0 ml of
DMEM with added FCS, antibiotics, and 1.0 
 
m
 
g/ml puromycin.
The cells were incubated with virus for 24 h at 37
 
8
 
C, washed
three times, and samples of the culture supernatants were taken
on days 0, 4, 7, 10, and 14 for HIV-1 p24 antigen measurements.
 
Chemokine Blocking.
 
Biologically cloned isolates of HIV-1
were used to infect PHA-stimulated, normal PBMCs in the pres-
ence of increasing concentrations of recombinant human RANTES,
MIP-1
 
a
 
 and -1
 
b
 
 (R&D Sys., Inc., Minneapolis, MN). PBMCs
(2 
 
3
 
 10
 
6
 
) were infected with 200 TCID
 
50
 
 of each virus in 1.0 ml
of medium. Chemokines were serially diluted twofold and added
at the time of infection, such that the final concentration of each
chemokine was 500 ng/ml in the highest well. Control cultures
were set up in quadruplicate and infected in the absence of added
chemokines. After overnight incubation at 37
 
8
 
C, the cells were
washed and resuspended in medium containing the appropriate
concentration of chemokines. HIV-1 p24 antigen was measured
in the culture supernatants on day 7 after infection and the
amount of chemokine blocking was calculated as the percent in-
hibition of HIV-1 p24 antigen production compared to controls.
 
Single Cycle Infectivity Assays.
 
HIV-1 
 
env
 
 expression vectors
were generated by direct DNA PCR amplification and cloning
using sequential PBMC samples from patient B as previously de-
scribed (33). 
 
Env
 
 clones expressing full-length gp160/120 were
co-transfected with an 
 
env
 
 (
 
2
 
) luciferase reporter vector, pNL4-
3LucE
 
2
 
, to generate env-pseudotyped virions (34). Reporter vi-
ruses pseudotyped with either macrophage-tropic, NSI (HIV-1
 
JRFL
 
)
or TCLA SI (HIV-1
 
HXB2
 
) envelope glycoproteins were used as
controls. HOS.CD4 cells stably transfected with either CCR1,
CCR2b, CCR3, CCR4, CCR5, CXCR-4, or the retroviral ex-
pression vector (pBABE) were infected with each of the pseudo-
typed viruses (100 ng p24). Cells were lysed 4 d after infection
using 100 
 
m
 
l of luciferase lysis buffer (Promega Corp., Madison,
WI). The amount of luciferase activity in 20 
 
m
 
l of lysate was mea-
sured using commercially available reagents (Promega Corp.) in a
luminometer (Top Count; Packard Instrs., Meriden, CT).
 
Results
 
Use of CCR5, CCR3, CCR2b, and CXCR-4 by Sequen-
tial HIV-1 Isolates.
 
In initial experiments, sequential HIV-1
isolates from patients B, C, and D were used to infect
CD4
 
1
 
 cells expressing either CCR5, CCR3, CCR2b, or
CXCR-4. HIV-1 isolates obtained early in the course of
infection from all three patients replicated to low levels in
CD4
 
1
 
 cells expressing CCR5, but failed to replicate to de- 
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tectable levels in cells expressing either CCR2b, CCR3, or
CXCR-4 (Table 1). A similar pattern of infection was seen
with all subsequent isolates from patient D. However, se-
quential isolates from patients B and C showed a shift in re-
ceptor use which coincided with a switch from NSI to SI
phenotype. While viruses isolated at early time points from
these patients initially used only CCR5 for infection, vi-
ruses isolated later in the course of disease infected cells ex-
pressing either CCR5 or CXCR-4. In addition, several
later isolates from patient C replicated in cells expressing
CCR2b and CCR3 (Table 1). These results suggest that
HIV-1 variants arise during the course of infection that use
an expanded range of coreceptors for infection of CD4
 
1
 
cells. In particular, adaptation to use CXCR-4 as a core-
ceptor was associated with a switch from NSI to SI pheno-
type and a drop in CD4
 
1
 
 T cell counts.
Because primary HIV-1 isolates may consist of a mixture
of distinct variants with different phenotypes (3, 4), we
tested a panel of biologically cloned primary HIV-1 isolates
for their ability to infect CD4
 
1
 
 cells expressing CXCR-4
or the 
 
b
 
-chemokine receptors, CCR1, CCR2b, CCR3,
CCR4, and CCR5. These isolates were generated by lim-
iting dilution and co-culture of PBMCs from patient B;
five had an NSI phenotype (2-5, 3-1, 3-4, 4-1, 5-2), and
two were SI (5-7, 5-8). As shown in Table 2, all five of the
NSI viruses replicated in cells expressing CCR5. They did
not replicate to detectable levels in cells expressing the
other coreceptors, but replicated efficiently in control cul-
tures of PHA-stimulated normal donor PBMCs. Similarly,
the two SI viruses replicated well in control PBMC cul-
tures. However, their coreceptor use was restricted to cells
expressing CXCR-4; no replication was detected in cells
expressing CCR1, CCR2b, CCR3, CCR4, or CCR5. It
is not clear why some of the NSI biological clones repli-
cated to lower levels in cells expressing CCR5 compared
with others (Table 2; clones 2-5 and 5-2); however, these
isolates may be characteristic of viruses with a “slow/low”
phenotype (3), or alternatively, may be restricted at a post-
entry step in HOS.CD4 cells expressing CCR5.
To determine whether coreceptor use was associated
with sensitivity to chemokine blocking, we tested the bio-
logically-cloned viruses for blocking by either RANTES,
MIP-1
 
a
 
, -1
 
b
 
, or a combination of all three chemokines.
As shown in Fig. 1, the NSI viruses (2-5, 3-1, 3-4, 5-2)
were inhibited in a dose-dependent manner by addition of
RANTES, MIP-1
 
a
 
, and -1
 
b
 
, either alone or in combina-
tion with an IC
 
90
 
 of 75–119 ng/ml. In contrast, the two SI
isolates (5-7, 5-8) were only partially blocked, even at the
highest chemokine concentration (500 ng/ml). These re-
sults suggest that there is a loss of sensitivity to the blocking
effects of 
 
b
 
-chemokines that is associated with acquisition
of the ability to use CXCR-4 as a coreceptor for infection.
An NSI isolate from late stage infection (5-2) remained sen-
sitive to chemokine blocking consistent with its use of the
CCR5 coreceptor (Table 2).
Taken together, our results suggest that HIV-1 predomi-
 
Table 1.
 
Replication of Sequential Primary Isolates
 
Patient Date CD4 cells/mm
 
3
 
Phenotype
 
‡
 
p24 antigen
 
*
 
CCR2b CCR3 CCR5 CXCR-4
 
pg/ml
 
B 5/85 528 NSI
 
,
 
30
 
,
 
30 200
 
,
 
30
11/86 677 NSI
 
,
 
30
 
,
 
30 26,200
 
,
 
30
6/88 603 SI
 
,
 
30
 
,
 
30 29,500  400
11/88 117 SI
 
,
 
30
 
,
 
30 33,320 7,820
C 5/84 1,233 NSI
 
,
 
30
 
,
 
30 1,024
 
,
 
30
1/85 1,038 NSI
 
,
 
30
 
,
 
30 72,400
 
,
 
30
2/86 1,049 SI
 
,
 
30
 
,
 
30 84,800 1,666
7/86 485 SI
 
,
 
30
 
,
 
30 60,200 65,600
12/86 346 SI 16,240 12,700 31,000 43,100
5/87 141 SI 1,200 1,586 28,800 54,800
6/88 186 SI
 
,
 
30
 
,
 
30 30,200 19,460
11/89 38 SI 6,600 11,240 31,200 24,000
D 3/86 725 NSI
 
,
 
30
 
,
 
30 140
 
,
 
30
6/87 690 NSI
 
,
 
30
 
,
 
30 181
 
,
 
30
9/90 700 NSI
 
,
 
30
 
,
 
30 157
 
,
 
30
3/91 750 NSI
 
,
 
30
 
,
 
30 155
 
,
 
30
*HIV-1 p24 antigen was measured in culture supernatants on days 0, 4, 7, 10, and 14 after infection. Values represent the peak p24 levels measured
on either day 10 or 14. A value of ,30 pg/ml was considered negative.
‡The SI phenotype for each isolate was determined using MT-2 cells as previously described (5, 29).624 HIV-1 Coreceptors in Disease Progression
nantly uses a single coreceptor, CCR5, in the early stages
of infection. Variants using CXCR-4 appeared later and were
associated with a loss of sensitivity to chemokine blocking
in vitro. The presence later in infection of an isolate using
CCR5 as a coreceptor (5-2), is consistent with the persis-
tence of macrophage-tropic, NSI variants throughout the
course of infection (4).
Env-mediated Interaction. Fusion of HIV-1 with CD41
T cells is mediated by interaction of the viral envelope gly-
coproteins with coreceptors expressed on the cell surface
(15). Considerable variation in the env gene of HIV-1 oc-
curs throughout the course of infection and is associated
with changes in the tropism and SI properties of the virus.
It follows that these changes may reflect the efficiency with
which different viral envelope glycoproteins interact with
specific coreceptors.
To test this hypothesis, we generated full-length env
clones by direct DNA PCR amplification from sequential
PBMC samples from patient B (33). Env clones 9-12 and
13-14 were derived from early NSI viruses (Table 1; 5/85
and 11/86, respectively), whereas env clone 15-1 was de-
rived from an SI isolate (Table 1; 6/88). HIV-1 virions
containing a luciferase reporter gene were pseudotyped
with the cloned envelope glycoproteins and used in single
cycle infectivity assays to evaluate viral entry into CD41 cells
expressing each of the b-chemokine receptors or CXCR-4.
As shown in Fig. 2, luciferase activity was detected in cells
expressing CCR5, CCR3, and CCR2b after infection with
control viruses pseudotyped with envelope glycoproteins
from a macrophage-tropic, NSI strain of HIV-1 (HIV-1JRFL)
(Fig. 2 A). In contrast, a TCLA, SI virus (HIV-1HXB2) was
only able to infect cells expressing CXCR-4. Virions pseu-
dotyped with envelope glycoproteins from two of the pri-
mary env clones from patient B (9-12, 13-14) infected cells
expressing CCR5, and to a lesser extent, CCR2b and
CCR3, while a third clone (15-1) only infected cells ex-
pressing CXCR-4. Another primary HIV-1 env clone de-
rived from a long-term survivor (DH) used CCR5 and
CCR3 for infection. Sequencing of the V3 loop of env
clones 9-12, 13-14, and DH revealed the presence of un-
charged amino acids at positions 11 and 28 (Fig. 2 B), char-
acteristic of NSI viruses, while clone 15-1 had a positively
charged residue at position 11, characteristic of SI viruses
(35, 36).
Figure 1. Inhibition of sequential HIV-1 isolates by b-chemokines. Bi-
ologically cloned isolates of HIV-1 were used to infect PHA-activated
normal donor PBMCs in the presence of increasing concentrations of
RANTES (j), MIP-1a (d), MIP-1b (m), or all three combined (r).
HIV-1 p24 antigen was measured in culture supernatants on day 7 after
virus inoculation. The percent inhibition was calculated based on control
cultures infected without added chemokines.
Table 2. HIV-1 Coreceptor Use by Sequential Biologically Cloned Isolates
Sample date Isolate Phenotype PBMC
p24 antigen*
CCR1 CCR2b CCR3 CCR4 CCR5 CXCR-4
pg/ml
5/85 2-5 NSI 69,200 ,30 ,30 ,30 ,30 146 ,30
11/86 3-1 NSI 51,400 ,30 ,30 ,30 ,30 3,540 ,30
3-4 NSI 70,800 ,30 ,30 ,30 ,30 19,600 ,30
6/8 4-1 NSI 81,400 ,30 ,30 ,30 ,30 39,240 ,30
11/88 5-2 NSI 26,600 ,30 ,30 ,30 ,30 308 ,30
5-7 SI 53,800 ,30 ,30 ,30 ,30 ,30 1,202
5-8 SI 89,200 ,30 ,30 ,30 ,30 ,30 2,950
*HIV-1 p24 antigen was measured supernatants on days 0, 4, 7, 10, and 14 after infection. Values represent the peak p24 levels measured on day 10
or 14. A value of ,30 pg/ml was considered negative.625 Connor et al.
Discussion
In this study, we examined coreceptor use by sequential
primary isolates of HIV-1 obtained throughout the course
of infection. Our results indicate that disease progression is
associated with the appearance of viral variants able to use
an expanded range of coreceptors for infection of CD41
cells. HIV-1 isolates initially used a single coreceptor,
CCR5, for infection of CD41 cells in vitro. Later in the
course of disease, the virus expanded its coreceptor use to
include CCR5, CCR3, CCR2b, and CXCR-4. In partic-
ular, the appearance of viruses using CXCR-4 as a core-
ceptor was associated with a decline in CD41 T cell counts
and clinical progression to AIDS. In contrast, only viruses
capable of using CCR5 could be isolated from a third pa-
tient, who remained asymptomatic for over 10 yr after
HIV-1 infection with a low viral burden and normal CD41
T cell counts (5). These results indicate that the expanded
coreceptor use is not simply the result of increasing env di-
versity over time, but instead suggest that there may be a
selective advantage for viruses that can use coreceptors in
addition to CCR5.
Recent studies have identified CCR5 as an essential de-
terminant of sexual transmission (32). CD41 T-cells from
two multiply exposed/uninfected individuals were shown
to resist infection with macrophage-tropic, NSI strains of
HIV-1 (32, 37, 38) due to a 32–base pair deletion in the
gene encoding CCR5 (32). Our results indicate that viruses
using CCR5 persist during asymptomatic infection, and in
one patient, were present as long as 7 yr after seroconver-
sion. These viruses are typical of many primary NSI isolates
in that they exhibit a dual tropism for both CD41 T lym-
phocytes and macrophages. Both cells types are known to
express CCR5 and may be targets for these viruses in vivo.
The persistence of viruses using CCR5 suggests they may
escape immune surveillance mechanisms, possibly by seques-
tration in long-lived cell populations such as macrophages
or dendritic cells.
Selective pressure exerted by either specific or nonspeci-
fic immune mechanisms may lead to the evolution of HIV-1
variants with distinct coreceptor requirements. Because
CCR5 binds several b-chemokines, including RANTES,
MIP-1a, and -1b, selection may favor variants that can rep-
licate in the presence of high concentrations of these factors.
We identified several variants of HIV-1 that were resistant
to the blocking effects of exogenously added b-chemokines.
This resistance was associated with loss of the ability to use
CCR5 for infection. This suggests that HIV-1 may evolve
in vivo to use alternative coreceptors, such as CXCR-4, in
response to selection pressure exerted by the production of
b-chemokines. Given the high rate of HIV-1 turnover in
vivo (39, 40) and the small number of amino acid changes
necessary to alter the virus phenotype (35, 36), it is not yet
clear why these viruses do not emerge earlier. However, they
may be more sensitive to neutralization by HIV-1–specific
antibodies due to changes in the envelope glycoproteins, or
alternatively, they may be blocked by the presence of stro-
mal cell–derived factor 1, which was recently identified as
the ligand for CXCR-4 (26, 27).
Relatively subtle changes in the viral genome can influ-
ence both phenotype and coreceptor use. As few as two
amino acid changes in the V3 loop of env have been shown
to affect the ability of primary isolates to induce syncytium
formation in vitro (35, 36). Moreover, substitutions at two
amino acid positions in V3 were sufficient to overcome the
resistant phenotype of CD41 T cells from two exposed/
Figure 2. Coreceptor use by primary HIV-1 env-pseudotyped virions.
(A) HOS.CD4 expressing either CCR1, CCR2, CCR3, CCR4, CCR5,
or CXCR-4 were infected with HIV-1 virions carrying a luciferase re-
porter gene and pseudotyped with envelope glycoproteins from either
control viruses (HIV-1JRFL, HIV-1HXB2) or from primary virus env clones.
Three of the primary env clones came from a patient with rapid disease
progression (9-12, 13-14, 15-1), while the fourth clone was from a pa-
tient with long-term asymptomatic infection (DH). Luciferase activity
was calculated by subtracting the background measurements made using
env(2) virions and HOS.CD4 cells expressing only the retroviral vector,
pBABE. (B) Deduced amino acid sequences of the V3 domain of gp120
from cloned primary HIV-1 env genes. Bold type indicates amino acids at
positions 11 and 28 which are associated with the SI phenotype of the vi-
rus (35, 36).626 HIV-1 Coreceptors in Disease Progression
uninfected individuals to infection with SI strains of HIV-1
(38). This is presumably due to a change in coreceptor use
from CCR5, which is defective in these individuals (32), to
CXCR-4 or another functional coreceptor. Indeed, recent
reports have shown that use of both CCR3 and CCR5 is
dependent on the sequence of the V3 loop (19).
By cloning sequential env genes from an HIV-1 infected
individual, we have shown that coreceptor use is controlled
by the env gene of the virus, and have identified primary
HIV-1 variants with distinct coreceptor requirements. Pre-
viously, we found amino acid substitutions in the V3 loop
of these variants that were characteristic of an NSI to SI
switch in phenotype (37), and have now shown that the
corresponding env clones display a switch in coreceptor use
from CCR5 to CXCR-4. Although the exact mechanism
for this switch is unclear, it is possible that mutations in V3
may directly affect interaction of the virus with specific sites
on the coreceptor molecule or may indirectly influence
receptor binding by altering the global conformation of
gp120.
The appearance of HIV-1 variants able to use CXCR-4
as a coreceptor was associated with an increase in viral load
and a marked drop in CD41 T cell counts in the patients
we studied. It is not clear if these viruses are directly cyto-
pathic for CD41 T cells in vivo. The most straightforward
explanation is that the SI phenotype reflects adaptation of
HIV-1 to use CXCR-4 expressed on CD41 target cells in
vivo. Because the tissue distribution of CXCR-4 is much
broader than CCR5, this may allow the virus access to a
wider range of potential target cells, or alternatively, may
permit fusion with more permissive target cells, thereby fa-
cilitating HIV-1 replication and spread. Further studies will
be necessary to discriminate between these possibilities and
delineate the pathogenic mechanisms associated with CD41
T cell depletion in vivo and the role of HIV-1 coreceptor
use in this process.
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